Sanjiv Shah, MD
Cardiovascular Disease · Chicago, ILNPI 1699971556
Payments from drug & device makers
Across 273 payments — averaging $4279.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$389K
- Boston Scientific$273K
- Bayer$101K
- AstraZeneca$100K
- Novartis$61K
- E.r. Squibb & Sons, L.L.C.$39K
- plus $205K from 22 others
Across 35 payments — averaging $2656.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$48K
- Pfizer$18K
- Novartis Pharma AG$13K
- Novartis$11K
- Bayer$2K
- Boehringer Ingelheim International GmbH$80
What the payments were for
- Consulting fees$222,75190%
- Speaking & faculty fees$16,2127%
- Travel & lodging$3,5211%
- Food & beverage$3,5481%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 50 | $388,937 |
| Boston Scientific | 29 | $273,050 |
| Bayer | 24 | $101,340 |
| AstraZeneca(2 entities) | 15 | $99,954 |
| Novartis | 5 | $61,215 |
| E.r. Squibb & Sons, L.L.C. | 32 | $38,790 |
| Medtronic(2 entities) | 7 | $29,320 |
| Astrazeneca AB | 11 | $23,862 |
| Eli Lilly | 21 | $23,429 |
| Ionis Pharmaceuticals, Inc. | 9 | $20,977 |
| Novo Nordisk AS | 7 | $20,095 |
| Bridgebio Pharma, Inc. | 2 | $11,625 |
| Merck | 7 | $10,413 |
| Edwards Lifesciences | 16 | $9,538 |
| Regeneron | 4 | $9,360 |
| Janssen Research & Development, LLC | 3 | $9,250 |
| Astrazeneca UK Limited | 10 | $8,188 |
| Novartis Pharma AG | 5 | $8,009 |
| Eidos Therapeutics, Inc. | 1 | $6,290 |
| Lilly USA, LLC | 1 | $4,800 |
| Amgen | 1 | $3,016 |
| Roche Diagnostics International Ltd | 1 | $2,800 |
| Impulse Dynamics (USA) Inc. | 1 | $1,200 |
| Nevro Corp. | 6 | $880 |
| Boehringer Ingelheim International GmbH | 1 | $850 |
| Acerta Pharma LLC | 1 | $500 |
| Bristol Myers Squibb | 1 | $428 |
| Abiomed | 2 | $191 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$19,250
- VYNDAQEL$16,710
- JARDIANCE$13,450
- Attruby$11,625
- Kerendia$8,335
- LCZ696B_ENTRESTO_CARDIOVASCULAR$7,794
- OPSUMIT$6,750
- Non-Covered$5,200
- MK-1242$4,000
- MOUNJARO$3,600
- Elecsys Troponin T Gen 5 STAT$2,800
- CLINICAL TRIAL PRODUCT$1,500
- OPTIMIZER SMART SYSTEM$1,200
- Senza$745
- LCZ696D_ENTRESTO_CARDIOVASCULAR$145
- Impella$129
- Micra$125
How this compares
$1,168,308 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 56 | $1,262,243 |
| OpsumitMacitentan | 21 | $260,776 |
| Tyvaso DpiTreprostinil | 11 | $260,260 |
| JardianceEmpagliflozin | 119 | $158,736 |
| EliquisApixaban | 66 | $103,363 |
| FarxigaDapagliflozin Propanediol | 35 | $48,608 |
| EntrestoSacubitril/Valsartan | 36 | $44,760 |
| XareltoRivaroxaban | 21 | $34,695 |
| WegovySemaglutide | 18 | $23,796 |
| OzempicSemaglutide | 23 | $22,413 |
| Bumetanide | 99 | $2,875 |
| Midodrine Hcl | 26 | $2,332 |
| Spironolactone | 162 | $2,068 |
| Ranolazine ErRanolazine | 11 | $1,538 |
| Metoprolol Succinate | 71 | $1,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $388,937 | $1,365,606122 claims |
| AstraZenecaFarxiga | $99,954 | $48,60835 claims |
| NovartisEntresto | $61,215 | $44,76036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Chicago
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Nitasha SarswatChicago$2M
- Sandeep NathanChicago$1.1M
- Boaz AvitallChicago$663K
- Ravi PatelChicago$488K
- Lubna ChoudhuryChicago$476K
- Akhil NarangChicago$427K
- Amit AminChicago$407K
- Michael DavidsonChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.